Approval · Notice of Compliance 21707 · 2019
GALLIPRANT: Notice of Compliance 21707
Issued January 8, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21707
- Date
- January 8, 2019
- Company
- Elanco Canada LimitedGuelph, Ontario, Canada
- Product type
- Veterinary
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GALLIPRANT | 02484250 | Marketed |
| GALLIPRANT | 02484269 | Marketed |
| GALLIPRANT | 02484277 | Marketed |
Medicinal ingredients
- GRAPIPRANT 20 MG per TAB
- GRAPIPRANT 60 MG per TAB
- GRAPIPRANT 100 MG per TAB